CD274 and neoplasm: Biomarker-guided selection of patients, e.g., based on tumor cell PD-L1 expression in NSCLC [6] or microsatellite-instability-high (MSI-high) tumor type in colorectal cancer [7], has managed to enrich patients who gain long-term benefit from ICI in some tumor types.